Double attack on tough head & neck cancers shows promise
NCT ID NCT02979977
Summary
This study tested whether combining two existing cancer drugs, afatinib (a daily pill) and cetuximab (a weekly/bi-weekly IV infusion), could help control advanced head and neck cancer that had worsened after standard treatments. It involved 50 patients whose cancer had returned or spread. The main goal was to see if this combination could shrink tumors and slow the cancer's progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CANCERS OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale Cancer Center
New Haven, Connecticut, 06520-8028, United States
Conditions
Explore the condition pages connected to this study.